J.P. Morgan Sticks to Its Buy Rating for Tenet Healthcare (THC)

J.P. Morgan analyst Benjamin Rossi maintained a Buy rating on Tenet Healthcare yesterday and set a price target of $260.00. The company’s shares closed yesterday at $173.78.

Meet Samuel – Your Personal Investing Prophet

• Start a conversation with TipRanks’ trusted, data-backed investment intelligence
• Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

According to TipRanks, Rossi is an analyst with an average return of -4.0% and a 43.75% success rate. Rossi covers the Healthcare sector, focusing on stocks such as Universal Health, US Physical Therapy, and Tenet Healthcare.

Currently, the analyst consensus on Tenet Healthcare is a Strong Buy with an average price target of $246.93, which is a 42.09% upside from current levels. In a report released on May 14, Bank of America Securities also maintained a Buy rating on the stock with a $230.00 price target.

Based on Tenet Healthcare’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.37 billion and a net profit of $702 million. In comparison, last year the company earned a revenue of $5.22 billion and had a net profit of $406 million

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of THC in relation to earlier this year. Most recently, in March 2026, Paola M Arbour, the EVP & CIO of THC sold 6,500.00 shares for a total of $1,549,795.00.